Medicare Part D coverage · dicyclomine hydrochloride · RxCUI 2719470
dicyclomine hydrochloride 40 MG Oral Tablet
Per the CMS 2026 Part D formulary file, dicyclomine hydrochloride 40 MG Oral Tablet is covered by 129 Medicare Part D plans (2.6% of enrollable products), averaging Tier 3.8, with prior authorization required on 0% of covering formularies.
- 2.6%
- Plan coverage
- 129
- Plans covering
- T3.8
- Avg tier
- 0%
- Prior auth required
What the CMS Formulary Data Shows for dicyclomine hydrochloride 40 MG Oral Tablet
Per the CMS 2026 Part D formulary file, dicyclomine hydrochloride 40 MG Oral Tablet (RxNorm concept RXCUI 2719470, generic name dicyclomine hydrochloride) appears on 4 distinct formulary files spanning 129 Medicare Part D plan offerings - 2.6% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 2 to Tier 5, with a cross-plan average of Tier 3.8.
Real-world access to dicyclomine hydrochloride 40 MG Oral Tablet depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 887,927 Part D beneficiaries filled dicyclomine hydrochloride 40 MG Oral Tablet in 2023, with total plan-and-beneficiary spending of $53,307,717 and an average per-beneficiary annual cost of $60.04. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry dicyclomine hydrochloride 40 MG Oral Tablet today.
Coverage Details
- Formularies covering
- 4
- Plans covering
- 129
- Coverage rate
- 2.6%
- Tier range
- Tier 2 – Tier 5
- Average tier
- Tier 4, Non-Preferred
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 0% of formularies
2023 Medicare Spending
- Beneficiaries
- 887,927
- Total spending
- $53,307,717
- Avg per beneficiary
- $60.04
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering dicyclomine hydrochloride 40 MG Oral Tablet
100 Medicare Advantage plans with Part D drug coverage include this drug.
Show the next 30 plans
Showing top 50 of 100 plans.
Frequently Asked Questions
Is dicyclomine hydrochloride 40 MG Oral Tablet covered by Medicare Part D?
Yes, dicyclomine hydrochloride 40 MG Oral Tablet is covered by 129 Medicare Part D plans (2.6% of all Part D formularies).
What tier is dicyclomine hydrochloride 40 MG Oral Tablet on Medicare Part D plans?
dicyclomine hydrochloride 40 MG Oral Tablet averages Tier 3.8 across Part D plans, ranging from Tier 2 to Tier 5.
Does dicyclomine hydrochloride 40 MG Oral Tablet require prior authorization?
0% of Part D formularies require prior authorization for dicyclomine hydrochloride 40 MG Oral Tablet. Step therapy: 0%. Quantity limits: 0%.
How much does Medicare spend on dicyclomine hydrochloride 40 MG Oral Tablet?
In 2023, total Medicare Part D spending on dicyclomine hydrochloride 40 MG Oral Tablet was $53,307,717, covering 887,927 beneficiaries. The average spend per beneficiary was $60.04.
Read our methodology - how this data is sourced, computed, and verified.
Nationwide similar Part D drugs
Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.
Closest average formulary tier
- fingolimod 0.5 MG Oral Capsule T3.8
- alanine 5.4 MG/ML / arginine 12 MG/ML / aspartate 3.2 MG/ML / cysteine 0.16 MG/ML / glutamate 5 MG/ML / glycine 3.6 MG/ML / histidine 4.8 MG/ML / isoleucine 8.2 MG/ML / leucine 14 MG/ML / lysine 8.2 MG/ML / methionine 3.4 MG/ML / phenylalanine 4.8 MG/ML / proline 6.8 MG/ML / serine 3.8 MG/ML / taurine 0.25 MG/ML / threonine 4.2 MG/ML / tryptophan 2 MG/ML / tyrosine 2.4 MG/ML / valine 7.8 MG/ML Injectable Solution [PremaSol] T3.8
- risperidone 12.5 MG Injection [Risperdal] T3.8
- ledipasvir 90 MG / sofosbuvir 400 MG Oral Tablet T3.8
- 1.7 ML denosumab-bnht 70 MG/ML Injection [Bomyntra] T3.8
- dapsone 0.05 MG/MG Topical Gel T3.8